These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24570539)

  • 1. Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
    Funakoshi Y; Takeuchi Y; Maeda H
    Asian Cardiovasc Thorac Ann; 2013 Aug; 21(4):482-4. PubMed ID: 24570539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 6. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.
    Marech I; Vacca A; Gnoni A; Silvestris N; Lorusso V
    Tumori; 2013; 99(5):e241-4. PubMed ID: 24362878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
    Kozlov V; Karpov I; Kovalenko S; Shamanin V
    Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
    Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
    Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
    Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
    Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
    Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
    Hishida T; Nagai K; Mitsudomi T; Yokoi K; Kondo H; Horinouchi H; Akiyama H; Nagayasu T; Tsuboi M;
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):e69-71. PubMed ID: 20674944
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
    Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
    J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
    Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
    Nishimura H; Nakajima T; Itakura M; Shingyoji M; Iizasa T; Kimura H
    Intern Med; 2009; 48(21):1905-7. PubMed ID: 19881244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
    Mitsuya K; Nakasu Y; Mizokami Y; Takahashi T; Nakamura Y; Ono A; Toda Y; Yamamoto N; Harada H; Nishimura T
    No Shinkei Geka; 2012 Jun; 40(6):503-9. PubMed ID: 22647509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.